Depemokimab reduces asthma exacerbations similarly to other biologics.
Ann Allergy Asthma ImmunolMay 22, 2026 (epub)
Clinical ResearchAllergy & Immunology
Arnaud Bourdin, Ian D Pavord, Nicholas Ballew et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of depemokimab compared to other biologics in patients with severe type 2 asthma. The analysis included 17 trials for exacerbation rates and 22 for safety. The findings indicated no significant differences in annualized exacerbation rates between depemokimab and other biologics, although depemokimab showed fewer serious adverse events compared to dupilumab.
Key findings
- Depemokimab significantly reduced annualized exacerbation rates compared to placebo.
- No significant differences in exacerbation rates were found between depemokimab and other biologics.
- Fewer serious adverse events were observed with depemokimab than with dupilumab.
- The results were consistent across fixed- and random-effect models.
Why it matters
Understanding the comparative efficacy and safety of biologics is crucial for clinicians managing severe asthma, as it informs treatment decisions and patient management strategies.